Department of Pharmacy, University of Pisa, Pisa, Italy.
IUBMB Life. 2024 Dec;76(12):1234-1251. doi: 10.1002/iub.2905. Epub 2024 Aug 12.
Glioblastoma (GB) is a lethal brain tumor that rapidly adapts to the dynamic changes of the tumor microenvironment (TME). Mesenchymal stem/stromal cells (MSCs) are one of the stromal components of the TME playing multiple roles in tumor progression. GB progression is prompted by the immunosuppressive microenvironment characterized by high concentrations of the nucleoside adenosine (ADO). ADO acts as a signaling molecule through adenosine receptors (ARs) but also as a genetic and metabolic regulator. Herein, the effects of high extracellular ADO concentrations were investigated in a human glioblastoma cellular model (U343MG) and MSCs. The modulation of the purinome machinery, i.e., the ADO production (CD39, CD73, and adenosine kinase [ADK]), transport (equilibrative nucleoside transporters 1 (ENT1) and 2 (ENT2)), and degradation (adenosine deaminase [ADA]) were investigated in both cell lines to evaluate if ADO could affect its cell management in a positive or negative feed-back loop. Results evidenced a different behavior of GB and MSC cells upon exposure to high extracellular ADO levels: U343MG were less sensitive to the ADO concentration and only a slight increase in ADK and ENT1 was evidenced. Conversely, in MSCs, the high extracellular ADO levels reduced the ADK, ENT1, and ENT2 expression, which further sustained the increase of extracellular ADO. Of note, MSCs primed with the GB-conditioned medium or co-cultured with U343MG cells were not affected by the increase of extracellular ADO. These results evidenced how long exposure to ADO could produce different effects on cancer cells with respect to MSCs, revealing a negative feedback loop that can support the GB immunosuppressive microenvironment. These results improve the knowledge of the ADO role in the maintenance of TME, which should be considered in the development of therapeutic strategies targeting adenosine pathways as well as cell-based strategies using MSCs.
胶质母细胞瘤(GB)是一种致命的脑肿瘤,它能迅速适应肿瘤微环境(TME)的动态变化。间充质干细胞(MSCs)是 TME 的基质成分之一,在肿瘤进展中发挥多种作用。GB 的进展是由免疫抑制微环境所促使的,其特征是核苷腺苷(ADO)的浓度很高。ADO 通过腺苷受体(ARs)作为信号分子发挥作用,但也作为遗传和代谢调节剂发挥作用。在此,研究了高细胞外 ADO 浓度对人胶质母细胞瘤细胞模型(U343MG)和 MSCs 的影响。在这两种细胞系中,研究了嘌呤体机制的调节,即 ADO 的产生(CD39、CD73 和腺苷激酶[ADK])、转运(平衡核苷转运蛋白 1(ENT1)和 2(ENT2))和降解(腺苷脱氨酶[ADA]),以评估 ADO 是否可以在正或负反馈回路中影响其细胞管理。结果表明,GB 和 MSC 细胞在暴露于高细胞外 ADO 水平时表现出不同的行为:U343MG 对 ADO 浓度的敏感性较低,仅表现出 ADK 和 ENT1 的轻微增加。相反,在 MSC 中,高细胞外 ADO 水平降低了 ADK、ENT1 和 ENT2 的表达,这进一步维持了细胞外 ADO 的增加。值得注意的是,用 GB 条件培养基预培养或与 U343MG 细胞共培养的 MSC 不受细胞外 ADO 增加的影响。这些结果表明,长时间暴露于 ADO 可能会对癌症细胞产生不同于 MSC 的不同影响,揭示了一个负反馈环,可支持 GB 的免疫抑制微环境。这些结果提高了对 ADO 在维持 TME 中的作用的认识,在开发针对腺苷途径的治疗策略以及使用 MSC 的基于细胞的策略时,应考虑这一点。
Am J Physiol Regul Integr Comp Physiol. 2015-4-1
Purinergic Signal. 2024-6
Biomark Res. 2025-5-19
Neurooncol Adv. 2023-2-23
Cancers (Basel). 2022-8-20
J Med Chem. 2022-7-14